Asthma control and COPD symptom burden in patients using fixed-dose combination inhalers (SPRINT study).
Nicolas RocheVicente PlazaVibeke BackerJob van der PalenIsa CerveriChelo GonzalezGuilherme SafiotiIrma ScheepstraOliver PatinoDave SinghPublished in: NPJ primary care respiratory medicine (2020)
Previous studies have found suboptimal control of symptom burden to be widespread among patients with asthma and chronic obstructive pulmonary disease (COPD). The Phase IV SPRINT study was conducted in 10 countries in Europe to assess asthma disease control and COPD symptom burden in patients treated with a fixed-dose combination (FDC) of inhaled corticosteroids (ICS) and long-acting beta agonists (LABAs). SPRINT included 1101 patients with asthma and 560 with COPD; all were receiving treatment with an FDC of ICS/LABA, delivered via various inhalers. Data were obtained over a 3-month period, during a single routine physician's office visit. Asthma control was defined as Asthma Control Test (ACT) score >19. COPD symptom burden was assessed by COPD Assessment Test (CAT), with a CAT score <10 defining low COPD symptom burden. Among patients using any ICS/LABA FDC, 62% of patients with asthma had achieved disease control (ACT score >19) and 16% of patients with COPD had low symptom burden (CAT score <10).
Keyphrases
- chronic obstructive pulmonary disease
- lung function
- cystic fibrosis
- air pollution
- patient reported
- primary care
- end stage renal disease
- emergency department
- risk factors
- chronic kidney disease
- high intensity
- ejection fraction
- newly diagnosed
- electronic health record
- big data
- allergic rhinitis
- prognostic factors
- deep learning
- artificial intelligence